Finch, GB
Andrew Finch, Leicestershire GB
Patent application number | Description | Published |
---|---|---|
20130096977 | CALL FORWARD SYSTEM - An automated checkout call-forward (ECF) system comprises a queuing area for channelling customers, which leads to one or more checkouts. Each checkout comprises a service area and each checkout can be in either an available condition to accept a new customer, or in an unavailable condition. An indicator is capable of directing a customer to an available checkout. A sensor system is capable of detecting and providing output parameters indicative of the presence of one or more customers in the queuing area and the presence of one or more customers in the service area of each checkout. The automated ECF system is configured to identify any available checkouts based on interpreting the sensor output parameters and to instruct the indicator based on the identified available checkouts. | 04-18-2013 |
Andy Finch, Leicestershire GB
Patent application number | Description | Published |
---|---|---|
20100288990 | STANCHION WITH DISPLAY DEVICE - A stanchion for use in a barrier system in accordance with an embodiment of the present application includes a display device mounted at substantially eye level such that it is easily viewed by a user waiting in line in the barrier system. The display device may include interactive features to track user position or allow users to request information, input information or to conduct transactions while on line. | 11-18-2010 |
David Finch, East Sussex GB
Patent application number | Description | Published |
---|---|---|
20110193496 | CONTROL SYSTEMS - A lighting control system comprises an input for receiving a mains supply voltage; an output for providing an output voltage signal for powering plural lamps; a controller; a first transformer connected to the input and being for reducing the mains supply voltage to a reduced voltage; a second transformer having a secondary winding connected in series between the first transformer and the output and having a primary winding connected to the controller, the secondary and primary windings being arranged so as to induce a supplementary voltage in the secondary winding when said primary winding is energised. The controller is configured in a first phase to provide a first energising signal to the primary winding of the second transformer such as to supplement the reduced voltage provided by the first transformer, thereby to provide an output voltage signal that is greater than the reduced voltage signal; and in a second phase to short-circuit the primary winding of the second transformer, thereby to provide an output voltage signal substantially at the reduced voltage. The controller is configured in a third phase to provide a second energising signal to the primary winding of the second transformer such as to alter the reduced voltage provided by the first transformer, the second energising signal having a different voltage to the first energising signal, thereby to provide an output voltage signal in the third phase that is different to the output voltage signals provided in the first and second phases. | 08-11-2011 |
20110193497 | CONTROL SYSTEMS - A lighting control system comprises an input for receiving a mains supply voltage; an output for providing an output voltage signal for powering plural lamps; a controller; a first transformer connected to the input and being for reducing the mains supply voltage to a reduced voltage; a second transformer having a secondary winding connected in series between the first transformer and the output and having a primary winding connected to the controller, the secondary and primary windings being arranged so as to induce a supplementary voltage in the secondary winding when said primary winding is energised. The controller is configured in a first phase, to provide a first energising signal to the primary winding of the second transformer such as to supplement the reduced voltage provided by the first transformer, thereby to provide an output voltage signal that is greater than the reduced voltage signal and in a second phase, immediately following the first phase, to cease to provide the first energising signal to the primary winding of the second transformer, thereby to provide an output voltage signal in the second phase that is different to the output voltage signal provided in the first phase The controller includes a control input for receiving a control signal from a user, for allowing a user to configure one or more parameters of the lighting control system. | 08-11-2011 |
Derek Geoffrey Finch, Isle Of Wight GB
Patent application number | Description | Published |
---|---|---|
20100169890 | URGENCY BASED SCHEDULING - The present invention relates to a method of scheduling for multi-function radars. Specifically, the present invention relates to an efficient urgency-based scheduling method. | 07-01-2010 |
Derek Geoffrey Finch, Cowes Hampshire GB
Patent application number | Description | Published |
---|---|---|
20160069993 | WIND TURBINE MITIGATION IN RADAR SYSTEMS - Disclosed is an ATC Radar and a method of operating an ATC Radar, comprising the steps of: receiving In-phase (I) and Quadrature (Q) signals; | 03-10-2016 |
Donna Finch, Cambridge GB
Patent application number | Description | Published |
---|---|---|
20130149312 | COMPOSITIONS AND METHODS FOR TREATING COPD EXACERBATION - This disclosure relates to methods of treating exacerbation of chronic obstructive pulmonary disease (COPD) with antibodies and antagonists to interleukin 1 receptor 1 (IL-1R1) or IL-1α. | 06-13-2013 |
Donna K. Finch, Newmarket GB
Patent application number | Description | Published |
---|---|---|
20110008364 | ANTIBODIES TO TGF-BETA - The present invention relates to antibody molecules, in particular antibody molecules that bind Transforming Growth Factor beta (TGFβ), and uses thereof. More particularly, the invention relates to antibody molecules that bind and preferably neutralise TGFβ1, TGFβ2 and TGFβ3, so-called “pan-specific” antibody molecules, and uses of such antibody molecules. Preferred embodiments within the present invention are antibody molecules, whether whole antibody (e.g. IgG, such as IgG1 or IgG4) or antibody fragments (e.g. scFv, Fab, dAb). | 01-13-2011 |
20130243788 | ANTIBODIES TO TGF-BETA - The present invention relates to antibody molecules, in particular antibody molecules that bind. Transforming Growth Factor beta (TGFβ), and uses thereof. More particularly, the invention relates to antibody molecules that bind and preferably neutralise TGβ1, TGFβ2 and TGFβ3, so-called “pan-specific” antibody molecules, and uses of such antibody molecules. Preferred embodiments within the present invention are antibody molecules, whether whole antibody (e.g. IgG, such as IgG1 or IgG4) or antibody fragments (e.g. scFv, Fab, dAb). | 09-19-2013 |
Donna K. Finch, Horseheath GB
Patent application number | Description | Published |
---|---|---|
20140127230 | ANTIBODIES TO TGF-BETA - The present invention relates to antibody molecules, in particular antibody molecules that bind Transforming Growth Factor beta (TGFβ), and uses thereof. More particularly, the invention relates to antibody molecules that bind and preferably neutralise TGFβ1, TGFβ2 and TGFβ3, so-called “pan-specific” antibody molecules, and uses of such antibody molecules. Preferred embodiments within the present invention are antibody molecules, whether whole antibody (e.g. IgG, such as IgG1 or IgG4) or antibody fragments (e.g. scFv, Fab, dAb). | 05-08-2014 |
20150284456 | ANTIBODIES TO TGF-BETA - The present invention relates to antibody molecules, in particular antibody molecules that bind Transforming Growth Factor beta (TGFβ), and uses thereof. More particularly, the invention relates to antibody molecules that bind and preferably neutralise TGFβ1, TGFβ2 and TGFβ3, so-called “pan-specific” antibody molecules, and uses of such antibody molecules. Preferred embodiments within the present invention are antibody molecules, whether whole antibody (e.g. IgG, such as IgG1 or IgG4) or antibody fragments (e.g. scFv, Fab, dAb). | 10-08-2015 |
Donna Kirsty Finch, Cambridge GB
Patent application number | Description | Published |
---|---|---|
20140212429 | BINDING MEMBERS-513 - This invention relates to binding members, especially antibody molecules, specific for interleukin 1 receptor 1 (IL-1R1). For example, isolated binding members specific for IL-1R1 which competes with IL-1 and IL-1Ra for binding to IL-1R1 and binds Il-1R1 with a K | 07-31-2014 |
20160096895 | BINDING MEMBERS-513 - This invention relates to binding members, especially antibody molecules, specific for interleukin 1 receptor 1 (IL-1R1). For example, isolated binding members specific for IL-1R1 which competes with IL-1 and IL-1Ra for binding to IL-1R1 and binds Il-1R1 with a K | 04-07-2016 |
Donna Kirsty Finch, Cambridgeshire GB
Patent application number | Description | Published |
---|---|---|
20100221257 | BINDING MEMBERS-513 - This invention relates to binding members, especially antibody molecules, specific for interleukin 1 receptor 1 (IL-1R1). For example, isolated binding members specific for IL-1R1 which competes with IL-1 and IL-1Ra for binding to IL-1R1 and binds Il-1R1 with a K | 09-02-2010 |
20130078717 | BINDING MEMBERS-513 - This invention relates to binding members, especially antibody molecules, specific for interleukin 1 receptor 1 (IL-1R1). For example, isolated binding members specific for IL-1R1 which competes with IL-1 and IL-1Ra for binding to IL-1R1 and binds Il-1R1 with a K | 03-28-2013 |
Harry Finch, Berkshire GB
Patent application number | Description | Published |
---|---|---|
20120088763 | TRIAZOLOPYRIDINE DERIVATIVES AND THEIR THERAPEUTIC USE - Compounds of formula (I) are inhibitors of p38 MAP kinase, useful as anti-inflammatory agents in the treatment of inter alia, diseases of the respiratory tract wherein; R | 04-12-2012 |
Harry Finch, Buckinghamshire GB
Patent application number | Description | Published |
---|---|---|
20120264787 | Respiratory Disease Treatment - There is provided a pharmaceutical composition that is adapted for pulmonary administration by inhalation, which composition comprises a glitazone, such as pioglitazone or rosiglitazone, and one or more pharmaceutically acceptable carriers and/or excipients, and wherein the glitazone content of the composition consists of at least 95% by weight of the 5R enantiomer and less than 5% by weight of the 5S enantiomer. There is also provided a use and kit. | 10-18-2012 |
20130203716 | Inhaled Combination Therapy - There is provided the use of a methylxanthine derivative such as theophylline and a steroid in a synergistic combination for the treatment of chronic obstructive pulmonary disease, wherein the combination is administered by the inhaled route for pulmonary delivery. | 08-08-2013 |
20140248357 | Respiratory Disease Treatment - A pharmaceutical composition adapted for pulmonary administration by inhalation is described, wherein the composition comprises a glitazone and one or more pharmaceutically acceptable carriers and/or excipients, wherein the glitazone content of the composition consists of at least 95% by weight of the 5R enantiomer and less than 5% by weight of the 5S enantiomer, and wherein the glitazone is pioglitazone or rosiglitazone or a pharmaceutically acceptable salt thereof, and wherein the glitazone is in the form of microparticles. | 09-04-2014 |
Harry Finch, Cambridge GB
Patent application number | Description | Published |
---|---|---|
20100105651 | ANTAGONISTS OF SNS SODIUM CHANNELS - Compounds of the formula (I), and pharmaceutically acceptable salts thereof, are found to be antagonists of SNS sodium channels. They are therefore useful as analgesic and neuroprotective agents, formula (I): R | 04-29-2010 |
20100204224 | AZACYCLIC COMPOUNDS AS INHIBITORS OF SENSORY NEURONE SPECIFIC SODIUM CHANNELS - Compounds of the formula (I), and pharmaceutically acceptable salts thereof, are found to be antagonists of SNS sodium channels. They are therefore useful as analgesic and neuroprotective agents; wherein (1) represents (A), (B) or (C); R | 08-12-2010 |
Harry Finch, Slough GB
Patent application number | Description | Published |
---|---|---|
20130123278 | PYRIMIDINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF RESPIRATORY DISEASES SUCH AS COPD - Compounds of formula (I) are inhibitors of neutrophil elastase, wherein A is C—R | 05-16-2013 |
20130150380 | PYRIMIDINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF RESPIRATORY DISEASES SUCH AS COPD - Compounds of formula (I) are inhibitors of neutrophil elastase, wherein A is C—R | 06-13-2013 |
Harry Finch, Harlow GB
Patent application number | Description | Published |
---|---|---|
20080318912 | Medicaments for Treating Chronic Respiratory Disease - There is provided the use of a methylxanthine compound and a steroid in a synergistic combination for the treatment of a respiratory disease, wherein the methylxanthine compound is administered at a dose, which, in isolation, is not effective to treat said disease. | 12-25-2008 |
20100324002 | Inhaled combination therapy - There is provided the use of a methylxanthine derivative such as theophylline and a steroid in a synergistic combination for the treatment of chronic obstructive pulmonary disease, wherein the combination is administered by the inhaled route for pulmonary delivery. | 12-23-2010 |
20110319446 | BICYCLO[2.2.1]HEPT-7-YLAMINE DERIVATIVES AND THEIR USES - Compounds of formula (I) have muscarinic M3 receptor modulating activity; | 12-29-2011 |
Harry Finch, Abington GB
Patent application number | Description | Published |
---|---|---|
20100179138 | Isozazole Compounds As Inhibitors Of Heat Shock Proteins - Isoxazoles of formula (A) or (B) are inhibitors of HSP90 activity, and useful for treatment of, for example cancers: | 07-15-2010 |
20120252797 | Isoxazole Compounds As Inhibitors Of Heat Shock Proteins - Isoxazoles of formula (A) or (B) | 10-04-2012 |
20130289026 | Isoxazole Compounds As Inhibitors Of Heat Shock Proteins - Isoxazoles of formula (A) or (B) are inhibitors of HSP90 activity, and useful for treatment of, for example cancers: | 10-31-2013 |
Harry Finch, Harlow Essex GB
Patent application number | Description | Published |
---|---|---|
20120027692 | PYRROLOPYRIMIDINEDIONE AND ITS THERAPEUTIC USE - The compound of formula (I) is an inhibitor of human neutrophil elastase, useful for inhalation treatment of pulmonary inflammation. | 02-02-2012 |
Robert Louis Finch, Flintshire GB
Patent application number | Description | Published |
---|---|---|
20140141262 | VINYL ALCOHOL POLYMERS WITH SILANE SIDE CHAINS AND COMPOSITIONS COMPRISING THE SAME - A functionalized homopolymer or copolymer of vinyl alcohol of the formula P—(R) | 05-22-2014 |
Simon Finch, Newmarket GB
Patent application number | Description | Published |
---|---|---|
20140132340 | INTEGRATED CIRCUIT - An integrated circuit comprising: a first core circuit configured to operate at a first clock rate for carrying out a first range of tasks; and a second core circuit configured to operate in a first mode and a second mode, the second core circuit being configured to operate at a second clock rate for carrying out a second range of tasks in the second mode and being configured to operate in the second mode when the first core circuit carries out the first range of tasks, the second clock rate being greater than the first clock rate. | 05-15-2014 |
20160085538 | OVER-THE-AIR UPDATES FOR BLE DEVICES - A method for updating a Bluetooth Low Energy (BLE) device from a host device, the BLE device including a processor, a non-volatile memory and a volatile memory, and being capable of data transfer via a Human Interface Device (HID) service, said non-volatile memory including partitions for a plurality of application images, said method including configuring a pointer to instruct the processor to copy a first application image in a first partition of the non-volatile memory to the volatile memory when the device starts up; transferring a second application image from the host device to a second partition of the non-volatile memory using Bluetooth HID service; and re-configuring the pointer to instruct the processor to copy the second application image in the second partition of the non-volatile memory to the volatile memory when the device next starts up if the second application image is error free. | 03-24-2016 |
Stephen Finch, Waterside GB
Patent application number | Description | Published |
---|---|---|
20130177475 | SHOWER STERILISATION SYSTEM AND METHOD OF USE THEREOF - A shower sterilisation system is provided. The system comprises shower apparatus including water supply means ( | 07-11-2013 |
Steven Caffall Finch, London GB
Patent application number | Description | Published |
---|---|---|
20090090070 | Railway arch linings and mezzanine floors - A system for lining arched structures, particularly railway arches ( | 04-09-2009 |